Navigation Links
Alba Therapeutics Corporation Reports Preliminary Phase IIa,Clinical Trial Results for AT-1001 for the Treatment of Celiac,Disease

ral symptoms and outcomes improved at statistically significant levels. -- Safety and tolerability of multiple oral doses of AT-1001 in the patient population was demonstrated. There were no Severe Adverse Events and all Adverse Events were reported as mild or moderate.

"We are very encouraged by the preliminary data and look forward to applying the extensive knowledge gained in this Phase IIa exploratory clinical trial to a larger, highly powered Phase IIb gluten challenge study later this year" said Blake Paterson, M.D., Chief Executive Officer of Alba Therapeutics. Using the highly complex and ambitious seven arm study design for the Phase IIa trial, we repeated the proof of concept from the Phase Ib study, showed a statistically significant effect across a variety of measures and are well prepared to move the celiac program forward."

Based on these results, Alba will advance AT-1001 into a Phase IIb clinical study in CD subjects during the third quarter of 2007. The Phase IIb study, to be performed in multiple centers in the United States and Canada, will assess the efficacy of AT-1001 utilizing multiple endpoints, including a composite index of disease activity. The first patient is expected to be enrolled into this study in the third quarter of 2007, and the study should conclude in early 2008.

About Celiac Disease

Celiac Disease is a T-cell mediated autoimmune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, CD affects approximately 3 million Americans. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for some patients.

About Alba

Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Ma
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
(Date:12/26/2014)... December 26, 2014 “Many people become ... personal injury claim issues and phone calls with insurance ... an article featuring their free eBook on pedestrian ... eBook on pedestrian and bicycle auto accident claims assures ... fully capable of professionally handling their case while they ...
(Date:12/26/2014)... December 26, 2014 Parker & ... the best in heating, cooling and plumbing contractor ... hour emergency services in 2014 with regard to ... that Arizona is known for its incredibly hot ... understands the intricacies and details of a wide ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... be reduced if operating room staff borrowed team-building procedures ... A program that trained operating room workers to ... and to review what went right or wrong after ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... before heart surgery suffered fewer heart attacks, stroke and ... had better survival rates, two new studies find. ... bypass, valve or other scheduled cardiac surgeries. Of those, ...
... 19, 2010A rare and deadly form of breast cancer ... is the focus of a new report from leading ... an unrecognized and misunderstood form of breast cancer. It ... has lower overall survival compared to other breast cancers. ...
... a child or a dog play is not a foreign sight. ... Apparently, they play, too. In fact, according to Gordon Burghardt, ... -- not just dogs, cats, and monkeys -- need a little ... juvenile reptiles for many years and never saw anything that I ...
... Reporter , MONDAY, Oct. 18 (HealthDay News) -- ... medical mistakes, ranging from an operation on the wrong ... a new study finds. To try to curb ... 2004 introduced a universal protocol for all hospitals, ambulatory ...
... and quality of life for older people, but is also ... The research will be presented today,s at the Scientific Program ... East-Africa Council of Ophthalmology (MEACO) Joint Meeting. Cataract surgery not ... but is also apparently a way to reduce the number ...
Cached Medicine News:Health News:Lessons From Flight Crews Can Help Surgical Teams Work Better 2Health News:Lessons From Flight Crews Can Help Surgical Teams Work Better 3Health News:Aspirin, Statins May Reduce Problems After Heart Surgery 2Health News:Aspirin, Statins May Reduce Problems After Heart Surgery 3Health News:Inflammatory breast cancer focus of new report 2Health News:UT professor defines play, discovers even turtles need recess 2Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 2Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 3Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 4Health News:Cataract surgery saves lives, dollars by reducing auto crashes 2
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... best value in high performance electronic pipetting!, ... lightweight design reduce hand fatigue and strain ... tip ejector , Color coding for easy ... for greater performance use Hamilton AdvanTip Low ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
Medicine Products: